search
Back to results

Artificial Pancreas and Remote Monitoring During a T1DM Youth Ski Camp

Primary Purpose

Type 1 Diabetes Mellitus

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Tandem t:slim X2 with Control-IQ Technology + Dexcom G6
Dexcom CGM G5
Continuous Subcutaneous Insulin Infusion
Sponsored by
University of Virginia
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Type 1 Diabetes Mellitus focused on measuring Artificial Pancreas (AP), Continuous Glucose Monitor (CGM), Closed Loop Control (CLC), Insulin Pump

Eligibility Criteria

6 Years - 18 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Criteria for documented hyperglycemia (at least 1 must be met):

    • Clinical diagnosis of type 1 diabetes (C-peptide levels and antibody determinations are not required)
    • The diagnosis of type 1 diabetes is based on the investigator's judgment
  2. Criteria for requiring insulin at diagnosis (both criteria must be met):

    • Daily insulin therapy for ≥ 6 months
    • Insulin pump therapy for ≥ 3 months (note: must be willing to disable any glucose suspend, predictive suspend, or artificial pancreas functionality on insulin pump during study)
  3. Virginia camp: age 13-18 years; Colorado/Stanford camps: 6-12 years
  4. Avoidance of acetaminophen-containing medications (i.e. Tylenol) while wearing the continuous glucose monitor.
  5. Willingness to wear a continuous glucose sensor and physiological monitor for the duration of the study
  6. Not being pregnant at the start of the trial. All female subjects of childbearing potential will be screened for pregnancy.

8. If the participant is less than 13 years of age and the parents or the study team request it, at least one parent commit to stay with the study subject at the camp site 9. A parent/caregiver is available for system training and will commit to be the main responsible person for the use of the AP system at home

Exclusion Criteria:

  1. Diabetic ketoacidosis in the past 6 months
  2. Hypoglycemic seizure or loss of consciousness in the past 6 months
  3. History of seizure disorder (except for hypoglycemic seizure)
  4. History of any heart disease including coronary artery disease, heart failure, or arrhythmias
  5. History of altitude sickness
  6. Chronic pulmonary conditions that could impair oxygenation
  7. Cystic fibrosis
  8. Current use of oral glucocorticoids, beta-blockers or other medications, which in the judgment of the investigator would be a contraindication to participation in the study.
  9. History of ongoing renal disease (other than microalbuminuria).
  10. Subjects requiring intermediate or long-acting insulin (such as NPH, Detemir or Glargine).
  11. Subjects requiring other anti-diabetic medications other than insulin (oral or injectable).
  12. Pregnancy
  13. Presence of a febrile illness within 24 hours of start ski camp or acetaminophen use while wearing the CGM. The camp study subject will not participate in the trial if these conditions are met.
  14. Medical or psychiatric condition that in the judgment of the investigator might interfere with the completion of the protocol such as (for parent and/or child):

    • Inpatient psychiatric treatment in the past 6 months
    • Uncontrolled adrenal insufficiency
    • Alcohol abuse

Sites / Locations

  • Stanford University
  • Barbara Davis Center, University of Colorado
  • University of Virginia Center for Diabetes Technology

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Artificial Pancreas Therapy

Sensor Augmented Pump Therapy

Arm Description

Subjects will use the Tandem t:slim X2 with Control-IQ Technology + Dexcom G6 to automatically modulate their insulin delivery and control their glycemia. In addition a Dexcom G5 Share/Follow system will be used to remote monitor the participants and ensure safety.

Subjects will use a Dexcom CGM G5 and their Continuous Subcutaneous Insulin Infusion devices (insulin pumps) to modulate their insulin delivery and control their glycemia. In addition a Dexcom G5 Share/Follow system will be used to remote monitor the participants and ensure safety.

Outcomes

Primary Outcome Measures

Percent time spent in glycemic zone (70-180mg/dl)
Primary outcome will be the percent time spent in desirable glycemic zone (70-180mg/dl) during the entirety of the camp.

Secondary Outcome Measures

Full Information

First Posted
November 15, 2017
Last Updated
August 10, 2018
Sponsor
University of Virginia
Collaborators
Tandem Diabetes Care, Inc., DexCom, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT03369067
Brief Title
Artificial Pancreas and Remote Monitoring During a T1DM Youth Ski Camp
Official Title
Real-Time Monitoring and Glucose Control During Winter-Sport Exercise in Youth With Type 1 Diabetes: The AP Ski Camp Continued
Study Type
Interventional

2. Study Status

Record Verification Date
August 2018
Overall Recruitment Status
Completed
Study Start Date
December 18, 2017 (Actual)
Primary Completion Date
April 15, 2018 (Actual)
Study Completion Date
April 15, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Virginia
Collaborators
Tandem Diabetes Care, Inc., DexCom, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
An early feasibility study that will test the efficacy of the Tandem t:slim X2 with Control-IQ and Dexcom Continuous Glucose System G6 in a winter/ski camp environment.
Detailed Description
This proposal aims to demonstrate the superiority of the Closed-Loop Control (CLC), also known as Artificial Pancreas (AP) named Tandem t:slim X2 with Control-IQ Technology and assess usability in a supervised setting in a controlled environment compared with state-of-the-art Sensor-Augmented Pump (SAP) therapy for the treatment of type 1 diabetes (T1D) in adolescents.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 1 Diabetes Mellitus
Keywords
Artificial Pancreas (AP), Continuous Glucose Monitor (CGM), Closed Loop Control (CLC), Insulin Pump

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
55 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Artificial Pancreas Therapy
Arm Type
Experimental
Arm Description
Subjects will use the Tandem t:slim X2 with Control-IQ Technology + Dexcom G6 to automatically modulate their insulin delivery and control their glycemia. In addition a Dexcom G5 Share/Follow system will be used to remote monitor the participants and ensure safety.
Arm Title
Sensor Augmented Pump Therapy
Arm Type
Placebo Comparator
Arm Description
Subjects will use a Dexcom CGM G5 and their Continuous Subcutaneous Insulin Infusion devices (insulin pumps) to modulate their insulin delivery and control their glycemia. In addition a Dexcom G5 Share/Follow system will be used to remote monitor the participants and ensure safety.
Intervention Type
Device
Intervention Name(s)
Tandem t:slim X2 with Control-IQ Technology + Dexcom G6
Other Intervention Name(s)
Artificial Pancreas, Automated Insulin Delivery Device
Intervention Description
Subjects will use the Tandem t:slim X2 with Control-IQ Technology and Dexcom G6 CGM to control their glycemia. The Tandem t:slim X2 with Control-IQ device is an automated insulin delivery pump that automatically adjusts insulin delivery to predicted and prevailing glucose levels, as measured by a Dexcom G6 continuous glucose monitor [CGM].
Intervention Type
Device
Intervention Name(s)
Dexcom CGM G5
Other Intervention Name(s)
Continuous Glucose monitoring
Intervention Description
The Dexcom G5 CGM is a subcutaneous glucose sensor that provides an estimate of the prevailing blood glucose concentration approximately every 5 minutes.The Dexcom G5 sensor alerts the user if the prevailing glucose concentration is higher or lower than predetermined thresholds, or if it is changing too fast. In addition, the Share/Follow functionality of the Dexcom G5 allows up to 5 people ("followers") to receive in real-time information about the current blood glucose concentration and rate of change. The Dexcom G5 system will be used by participants and clinical study staff to monitor glucose levels 24h/day during the camp, ensure participants safety, and compute glycemic control outcomes
Intervention Type
Device
Intervention Name(s)
Continuous Subcutaneous Insulin Infusion
Other Intervention Name(s)
Insulin pump
Intervention Description
Subjects will use a subcutaneous pump to deliver insulin and control their glycemia.
Primary Outcome Measure Information:
Title
Percent time spent in glycemic zone (70-180mg/dl)
Description
Primary outcome will be the percent time spent in desirable glycemic zone (70-180mg/dl) during the entirety of the camp.
Time Frame
up to 48 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Years
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Criteria for documented hyperglycemia (at least 1 must be met): Clinical diagnosis of type 1 diabetes (C-peptide levels and antibody determinations are not required) The diagnosis of type 1 diabetes is based on the investigator's judgment Criteria for requiring insulin at diagnosis (both criteria must be met): Daily insulin therapy for ≥ 6 months Insulin pump therapy for ≥ 3 months (note: must be willing to disable any glucose suspend, predictive suspend, or artificial pancreas functionality on insulin pump during study) Virginia camp: age 13-18 years; Colorado/Stanford camps: 6-12 years Avoidance of acetaminophen-containing medications (i.e. Tylenol) while wearing the continuous glucose monitor. Willingness to wear a continuous glucose sensor and physiological monitor for the duration of the study Not being pregnant at the start of the trial. All female subjects of childbearing potential will be screened for pregnancy. 8. If the participant is less than 13 years of age and the parents or the study team request it, at least one parent commit to stay with the study subject at the camp site 9. A parent/caregiver is available for system training and will commit to be the main responsible person for the use of the AP system at home Exclusion Criteria: Diabetic ketoacidosis in the past 6 months Hypoglycemic seizure or loss of consciousness in the past 6 months History of seizure disorder (except for hypoglycemic seizure) History of any heart disease including coronary artery disease, heart failure, or arrhythmias History of altitude sickness Chronic pulmonary conditions that could impair oxygenation Cystic fibrosis Current use of oral glucocorticoids, beta-blockers or other medications, which in the judgment of the investigator would be a contraindication to participation in the study. History of ongoing renal disease (other than microalbuminuria). Subjects requiring intermediate or long-acting insulin (such as NPH, Detemir or Glargine). Subjects requiring other anti-diabetic medications other than insulin (oral or injectable). Pregnancy Presence of a febrile illness within 24 hours of start ski camp or acetaminophen use while wearing the CGM. The camp study subject will not participate in the trial if these conditions are met. Medical or psychiatric condition that in the judgment of the investigator might interfere with the completion of the protocol such as (for parent and/or child): Inpatient psychiatric treatment in the past 6 months Uncontrolled adrenal insufficiency Alcohol abuse
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Marc Breton, PhD
Organizational Affiliation
University of Virginia Center for Diabetes Technology
Official's Role
Principal Investigator
Facility Information:
Facility Name
Stanford University
City
Stanford
State/Province
California
ZIP/Postal Code
94304
Country
United States
Facility Name
Barbara Davis Center, University of Colorado
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States
Facility Name
University of Virginia Center for Diabetes Technology
City
Charlottesville
State/Province
Virginia
ZIP/Postal Code
22903
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Artificial Pancreas and Remote Monitoring During a T1DM Youth Ski Camp

We'll reach out to this number within 24 hrs